Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2010

The Pharma Closeout tracks 44 deals, $120.8B in disclosed deal value, 39 with a post-close Outcome Score for the year 2010.

Median Critic Score: 71  ·  Median Outcome Score: 33

Best outcome: Pfizer Inc. / FoldRx Pharmaceuticals (99)  ·  Weakest outcome: Eli Lilly and Company / Alnara Pharmaceuticals (13)

All 44 deals

• Pfizer Inc. / FoldRx Pharmaceuticals — 2010 · Worked — the deal delivered on its rationale.
• Merck KGaA / Millipore Corporation — 2010 · $7.2B · Worked — the deal delivered on its rationale.
• Celgene Corporation / Agios Pharmaceuticals Inc. — 2010 · $130M · Worked — the deal delivered on its rationale.
• Thermo Fisher Scientific Inc. / Dionex Corporation — 2010 · $2.1B · Worked — the deal delivered on its rationale.
• Sanofi SA / Genzyme Corporation — 2010 · $18.5B · Worked — the deal delivered on its rationale.
• Laboratory Corporation of America Holdings / Genzyme Genetics (business unit) — 2010 · $925M · Largely worked — most objectives met.
• Grifols SA / Talecris Biotherapeutics Holdings Corp. — 2010 · $3.4B · Largely worked — most objectives met.
• Celgene Corporation / Abraxis BioScience Inc. — 2010 · $2.9B · Largely worked — most objectives met.
• Sekisui Chemical Co., Ltd. / Genzyme Diagnostic Products business — 2010 · $265M · Largely worked — most objectives met.
• Merit Medical Systems / BIOSPHERE MEDICAL INC — 2010 · $96M · Largely worked — most objectives met.
• Watson Pharmaceuticals, Inc. / Eden Biodesign Limited — 2010 · $15M · Largely worked — most objectives met.
• Mylan Inc. / Bioniche Pharma Holdings Limited — 2010 · $550M · Largely worked — most objectives met.
• Roche Holding AG / BioImagene, Inc. — 2010 · $100M · Mixed — partial payoff, real shortfalls.
• Abbott Laboratories / Piramal Healthcare (Healthcare Solutions Business) — 2010 · $3.7B · Mixed — partial payoff, real shortfalls.
• Stryker Corporation / Gaymar Industries — 2010 · $150M · Mixed — partial payoff, real shortfalls.
• Abbott Laboratories / Solvay Pharmaceuticals — 2010 · $6.2B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / Avid Radiopharmaceuticals, Inc. — 2010 · $800M · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Crucell N.V. — 2010 · $2.4B · Mixed — partial payoff, real shortfalls.
• Shire plc / Movetis NV — 2010 · $565M · Underwhelmed — fell short of the thesis.
• Sanofi SA / TargeGen, Inc. — 2010 · $560M · Underwhelmed — fell short of the thesis.
• Novartis AG / Alcon Inc. — 2010 · $51.6B · Underwhelmed — fell short of the thesis.
• Abbott Laboratories / Facet Biotech Corporation — 2010 · $722M · Underwhelmed — fell short of the thesis.
• Astellas Pharma Inc. / OSI Pharmaceuticals, Inc. — 2010 · $4.0B · Underwhelmed — fell short of the thesis.
• Roche Holding AG / Medingo Ltd. — 2010 · $160M · Did not work — the deal failed to deliver.
• Hospira, Inc. / Javelin Pharmaceuticals, Inc. — 2010 · $145M · Did not work — the deal failed to deliver.
• Cephalon, Inc. / Mepha AG — 2010 · $615M · Did not work — the deal failed to deliver.
• Hospira, Inc. / Orchid Chemicals & Pharmaceuticals (Generic Injectables Business) — 2010 · $400M · Did not work — the deal failed to deliver.
• Cephalon, Inc. / Ception Therapeutics — 2010 · $250M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Exelixis, Inc. (TGR5 + ROR programs) — 2010 · $565M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / SmartCells, Inc. — 2010 · $500M · Did not work — the deal failed to deliver.
• GlaxoSmithKline plc / Laboratorios Phoenix — 2010 · $253M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / ZymoGenetics, Inc. — 2010 · $885M · Did not work — the deal failed to deliver.
• Cephalon, Inc. / Mesoblast Limited — 2010 · $2.0B · Did not work — the deal failed to deliver.
• Valeant Pharmaceuticals International / Biovail Corporation — 2010 · $3.3B · Did not work — the deal failed to deliver.
• Endo Pharmaceuticals Holdings Inc. / HealthTronics, Inc. — 2010 · $223M · Did not work — the deal failed to deliver.
• Endo Pharmaceuticals Holdings Inc. / Qualitest Pharmaceuticals — 2010 · $1.2B · Did not work — the deal failed to deliver.
• Roche Holding AG / Anadys Pharmaceuticals, Inc. — 2010 · $230M · Did not work — the deal failed to deliver.
• Eli Lilly and Company / Alnara Pharmaceuticals — 2010 · $380M · Did not work — the deal failed to deliver.
• Endo Pharmaceuticals Holdings Inc. / Penwest Pharmaceuticals Co. — 2010 · $144M · Did not work — the deal failed to deliver.
• Pfizer Inc. / Biocon Limited (biosimilar insulin license) — 2010 · $350M
• AstraZeneca PLC / Rigel Pharmaceuticals, Inc. (Fostamatinib license) — 2010 · $1.2B
• Ipsen SA / Inspiration Biopharmaceuticals, Inc. — 2010 · $259M
• Bristol-Myers Squibb Company / Allergan, Inc. (EHT/AGN 0001 license) — 2010 · $413M
• Eli Lilly and Company / Acrux Limited (AXIRON license) — 2010 · $335M

← Deal Library  ·  Interactive search  ·  How we score deals